Analysis news
Every analysis development we have covered, newest first.
2 dated analysis items. Most recent: We re-checked sixteen compounded prices at source. Fifteen were wrong (2026-08-05).
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
All-in monthly cost at 10 mg
Stories in this category
We re-checked sixteen compounded prices at source. Fifteen were wrong
Every correction moved the price upward, which means published cheapest figures are systematical…
Three ownership structures, three risk profiles
Owned pharmacy, single contracted partner, or several named partners. The difference only become…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.